As of June 30, 2026, PhoenixBio Co., Ltd. carries a market capitalization of 1.34B, placing it among publicly traded companies globally. Its enterprise value stands at 538.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.34B |
| Enterprise Value | 538.96M |
PhoenixBio Co., Ltd.'s next confirmed earnings release is scheduled for February 12, 2027.
| Earnings Date | 2/12/2027 |
As of June 30, 2026, PhoenixBio Co., Ltd. has 4.07M shares outstanding.
| Shares Outstanding | 4.07M |
As of June 30, 2026, PhoenixBio Co., Ltd. trades at a trailing price-to-earnings ratio of 89.82. The price-to-sales ratio is 0.94, and the price-to-book ratio stands at 0.92.
| PE Ratio | 89.82 |
| PS Ratio | 0.94 |
| PB Ratio | 0.92 |
| P/TBV Ratio | 0.93 |
These figures are as of June 30, 2026. The EV/Sales ratio of 0.38 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 538.96M versus a market cap of 1.34B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 0.38 |
As of June 30, 2026, PhoenixBio Co., Ltd. maintains a current ratio of 4.20, meaning it holds 4.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.49, indicating elevated leverage, while an interest coverage ratio of -7.27 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.20 |
| Quick Ratio | 3.03 |
| Debt / Equity | 20.49 |
| Debt / EBITDA | -8.74 |
| Interest Coverage | -7.27 |
Over the twelve months ended June 30, 2026, PhoenixBio Co., Ltd. posted a return on equity (ROE) of 1.05, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -1.37, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.70, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 1.04, useful for judging operating efficiency across full business cycles. The company generates approximately 22.97M in revenue per employee across its workforce of 62.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.11 indicates how many times PhoenixBio Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 1.05 |
| Return on Assets (ROA) | 0.70 |
| Return on Invested Capital (ROIC) | -1.37 |
| Return on Capital Employed (ROCE) | 1.04 |
| Revenue Per Employee | 22.97M |
| Employee Count | 62.00 |
| Inventory Turnover | 1.11 |
Over the twelve months ended June 30, 2026, PhoenixBio Co., Ltd. recorded 6.35M in income tax expense. That works out to an effective tax rate of 29.80, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 21.30M, leaving 14.95M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 6.35M |
| Effective Tax Rate | 29.80 |
As of the close on November 17, 2026, PhoenixBio Co., Ltd.'s stock has declined approximately 43.79% over the past 52 weeks. The 50-day moving average sits at 298.76, while the 200-day moving average is 382.92.
| 52-Week Price Change | -43.79% |
| 50-Day Moving Average | 298.76 |
| 200-Day Moving Average | 382.92 |
Over the twelve months ended June 30, 2026, PhoenixBio Co., Ltd. generated 1.42B in revenue and converted that into 14.95M in net income, yielding earnings per share of 3.67. EBITDA reached -34.34M, while operating income came in at -34.33M.
| Revenue | 1.42B |
| Gross Profit | 1.07B |
| Operating Income | -34.33M |
| Pretax Income | 21.30M |
| Net Income | 14.95M |
| EBITDA | -34.34M |
| EBIT | -34.34M |
| Earnings Per Share (EPS) | 3.67 |
As of June 30, 2026, PhoenixBio Co., Ltd. holds 1.10B in cash and equivalents against 300.02M in total debt, resulting in a net debt position of -803.10M. Total book value stands at 1.46B, with working capital of 1.16B providing operational flexibility.
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 300.02M |
| Net Debt | -803.10M |
| Equity (Book Value) | 1.46B |
| Book Value Per Share | 359.77 |
| Working Capital | 1.16B |
Over the twelve months ended June 30, 2026, PhoenixBio Co., Ltd. posted a gross margin of 75.00, reflecting its pricing power and cost economics. The operating margin of -2.41 and net profit margin of 1.05 provide insight into operational efficiency.
| Gross Margin | 75.00 |
| Operating Margin | -2.41 |
| Pretax Margin | 1.50 |
| Profit Margin | 1.05 |
| EBITDA Margin | -2.41 |
As of June 30, 2026, PhoenixBio Co., Ltd. has an Altman Z-Score of 1.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 1.29 |
Already premium?